Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology.

ABSTRACT: The limited understanding of the heterogeneity in the treatment response to antidiabetic drugs contributes to metabolic deterioration and cardiovascular complications^1,2, stressing the need for more personalized treatment¹. Although recent attempts have been made to classify diabetes into subgroups, the utility of such stratification in predicting treatment response is unknown³. We enrolled participants with type 2 diabetes (n = 239, 74 women and 165 men) and features of severe insulin-deficient diabetes (SIDD) or severe insulin-resistant diabetes (SIRD). Participants were randomly assigned to treatment with the glucagon-like peptide 1 receptor agonist semaglutide or the sodium-glucose cotransporter 2 inhibitor dapagliflozin for 6 months (open label). The p

SUBMITTER: Dwibedi C 

PROVIDER: S-EPMC10822775 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature